Conference

First Human Data for AZD1613 and PYC-003 at Kidney Week

AstraZeneca's PAPPA antibody AZD1613 and PYC Therapeutics' PYC-003 both reported clean early safety data at ASN Kidney Week 2026, with early signs of target engagement.

Two first-in-class ADPKD drugs presented their first human data at ASN Kidney Week 2026 in Denver.

AZD1613 (AstraZeneca) is a human monoclonal antibody against PAPPA, an enzyme that frees growth-promoting IGF-1 inside cystic kidneys by cleaving its binding protein IGFBP4. In 64 healthy volunteers across eight single-dose cohorts (NCT06995820), there were no serious adverse events or discontinuations and no clinically significant lab, vital-sign or ECG changes. Exposure rose in proportion to dose, and cleaved IGFBP4 — the direct readout of PAPPA activity — stayed suppressed for more than 100 days. That sustained target inhibition is what the ongoing multiple-dose study in ADPKD patients (PIONEER-PKD) is building on.

PYC-003 (PYC Therapeutics) is an antisense drug that blocks microRNA-17 from binding PKD1 mRNA, aiming to raise production of polycystin-1, the protein that is deficient in ADPKD. In an oral presentation, PYC reported single doses up to 2.4 mg/kg in 18 ADPKD patients in the PINACLE-1 trial (NCT06714006), with no treatment-related serious adverse events or discontinuations. Urinary polycystin-1 showed a directional increase, and early kidney volume changes were described as directionally encouraging but needing confirmation in the repeat-dose cohorts now underway. PYC expects multiple-dose and extension data in 2027 and is describing a registrational Phase 2/3 trial as the next step.

Both readouts are early and exploratory, but they show two genuinely new approaches clearing the first hurdle. AbbVie/Calico's ANCHOR trial of ABBV-CLS-628, another PAPPA antibody, also presented its design: 240 patients at 72 sites in 12 countries, with no efficacy data yet.

Related Drugs in Pipeline

View all drugs in our PKD drug pipeline tracker.

Source

ASN Kidney Week 2026
AZD1613 PYC-003 ASN-2026 kidney-week phase-1

Disclaimer: This information is for educational purposes only and is not medical advice. News articles are based on publicly available data from ClinicalTrials.gov, company press releases, and published research. Consult your nephrologist before making treatment decisions.

Stay Updated on PKD Research

Get notified when new drugs enter clinical trials, trial results are published, or approved treatments change.

No spam. Unsubscribe anytime.